Results 131 to 140 of about 2,428,275 (198)

Synthetic peptide analogs derived from bcr/abl fusion proteins induce heteroclitic human T cell responses

Haematologica, 2005
M Yasukawa
doaj  

From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia. [PDF]

Leukemia
Hochhaus A, Talpaz M, Saglio G, Cortes JE, Hughes T, Apperley J, Hantschel O, Rea D, Schuld P, Kantarjian H.   +9 more
europepmc   +1 more source

Immunological mechanisms and therapeutic advances in chronic myeloid leukemia. [PDF]

Leukemia
Ybarra TK, Sathianathen RS, Hamidi R, Hijiya N, Shah NP, Sakamoto KM.   +5 more
europepmc   +1 more source

Olverembatinib for 8p11 myeloproliferative syndrome with a positive BCR-FGFR1 fusion gene: a case report. [PDF]

Ann Hematol
Wu M, Huang L, Yao Y, Xu Y, Yang Y, Luo J, Liu Z.   +6 more
europepmc   +1 more source

Exosome and BCR-ABL mediated molecular alterations in endothelial cells in chronic myeloid leukemia: identification of seven genes and their regulatory network. [PDF]

PeerJ
Shen Z, Cao H, Zhou Y, Mao W, Liu K, Zhu J, He M, Mao Y, Luo N, Feng L, Le H, Song L, Li H, Yousafzai YM, Zia A, Gu X, Zhang S.   +16 more
europepmc   +1 more source

Screening of kinase inhibitors in the triple negative KRAS G13D-mutated MDA-MB-231 breast cancer cell line. [PDF]

Sci Rep
Stickler S, Eggerstorfer MT, Rieche M, Arslan S, Teufelsbauer M, Hohenegger M, Weigl L, Hamilton G.   +7 more
europepmc   +1 more source

Case Report: Co-existence of <i>BCR::PDGFRA</i> gene fusion and <i>PDGFRA</i> variants in myeloid neoplasm with persistent leukocytosis, large splenomegaly, and eosinophilia. [PDF]

Front Oncol
Xiao Z, Lu C, Zhang P, Han N, He X, Zhang J, Feng Y, Guan M, Ouyang L, Gao Y, Li Y.   +10 more
europepmc   +1 more source

Reduced levels of ITGB1 cause activation of p38MAPK-ERK-LYN axis of BCR::ABL1 signaling despite inactivation of the oncoprotein by imatinib - novel resistance mechanism in blast crisis of chronic myeloid leukemia unraveled. [PDF]

Cell Commun Signal
Agrawal N, Narasimhan M, Mojidra R, Bagal B, Khattry N, Gokarn A, Punattar S, Govekar R.   +7 more
europepmc   +1 more source

Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia. [PDF]

Oncol Res
Tsubaki M, Matsuo T, Komori R.
europepmc   +1 more source

Synthetic peptide analogs derived from bcr/abl fusion proteins induce heteroclitic human T cell responses.

Haematologica, 2006
openaire   +2 more sources